Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. (Q43621488)

25 November 2017

title

Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. (English)

1 reference

25 November 2017

0 references

C Schmoor

1

1 reference

25 November 2017

W Sauerbrei

2

1 reference

25 November 2017

G Bastert

3

1 reference

25 November 2017

H Bojar

4

1 reference

25 November 2017

M Schumacher

5

1 reference

25 November 2017

German Breast Cancer Study Group

6

1 reference

25 November 2017

language of work or name

1 reference

1 June 2001

1 reference

European Journal of Cancer

25 November 2017

published in

1 reference

25 November 2017

volume

37

1 reference

25 November 2017

issue

9

1 reference

25 November 2017

page(s)

1123-1131

1 reference

Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Methodological arguments for the necessity of randomized trials in high-dose chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Much ado about not...enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years' follow-up. German Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Role of isolated locoregional recurrence of breast cancer: results of four prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Sample size considerations for the evaluation of prognostic factors in survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Statistical aspects of prognostic factor studies in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900090-9

7 January 2021

10.1016/S0959-8049(01)00090-9

Identifiers

DOI

1 reference

release_hrwyduw4bff77llvgj56xzvar4

25 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hrwyduw4bff77llvgj56xzvar4

24 November 2022

mapped directly with Wikidata item

1 reference